University of Crete (UOC)
Ανάλυση της έκφρασης προγνωστικών και προβλεπτικών δεικτών σε ασθενείς με μεταστατικό καρκίνο των ωοθηκών υπό θεραπεία με ανάλογα πλατίνας και ταξάνες
Abstract
dc:descriptionOvarian cancer is one of the most common cancers in women in the western world and has the highest mortality rate of all gynecological cancers. 90% of cases result from surface epithelium (epithelial ovarian cancer), and from the latter 40-50% of serous adenocarcinomas.The treatment option for Stage I-II cancer patients is total hysterectomy by removing the supplements supplemented with epilectomy. Most tumors, however, are diagnosed at an advanced stage (III), followed by a surgical exception to bring about a cytotoxication of the disease volume meter, followed by first-line chemotherapy with regimens containing a combination of platinum analogues and taxane.Of the treated patients, an objective response is 70-80% while the remainder (20-30%) shows residual or progressive drug resistance. The inability to predict patient response to specific treatments is a major barrier to improving the treatment of women with ovarian carcinoma, as chemotherapy is still empirical.Endogenous and acquired drug-resistance limit the efficacy of cancer chemotherapy and appear to be attributed to:for platinum, decreased cellular drug accumulation, increased cytoplasmic detoxification and increased DNA repair.for taxanes, drug transport, metabolism and pharmacodynamics.Finally, there are several preclinical and clinical data indicating that DNA polymorphisms, mRNA levels and gene mutations are involved in the metabolic pathways of platinum and taxane, thus most likely correlated with the outcome of the treatment and toxicity.In recent years, molecular mechanisms of platinum and taxane resistance have been identified through the expression of specific genes, which appears to affect the response of patients to chemotherapy. Nevertheless, there are still quite unclear points in both the imaging of the overall spectrum of molecular interactions and the harmonic correlation of molecular mechanisms of resistance with clinical dataBased on the above, a retrospective clinical pharmacogenomic study will be performed on ovarian carcinoma (EOC) stage Ic-IV women treated with first-line therapy with a platinum-taxane combination.The main purpose of this analysis will be to control the prognostic and / or predictive value of the genes: ATP7B (ATPase copper transporting beta), ERCC1 (ERCC excision repair 1, endonuclease non-catalytic subunit), BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated),UIMC1 (ubiquitin interaction motif containing 1 or RAP80),HOXA9 (homeobox A9),DAXX (death domain associated protein),T XN (thioredoxin ή TRX1), THBS1 (thrombospondin 1 or TSP1) and PRR13 (proline rich 13 or TXR1) investigating their involvement in cancer cell resistance in the two aforementioned categories of chemotherapeutics. An improper approach was made by controlling expression of proteins:p53, CRM1, DR4, DR5 and P27kip. The ultimate goal will be to build and evaluate a proactive biological model based on which personalized first-line chemotherapy will be given.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2017
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Pontikakis, Spyridon
- Ποντικάκης, Σπυρίδων
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42100